Express News | NYSE Order Imbalance 58165.0 Shares on Buy Side
Optimistic Buy Rating for Arcus Biosciences Based on Promising Efficacy and Safety Profile of Domvanalimab
Buy Rating on Arcus Biosciences: Unique Anti-TIGIT Antibody and Promising Cancer Trials Fuel Optimism
Express News | Arcus Biosciences Inc. : Morgan Stanley Raises Target Price to $40.00 From $38.00
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
Analysts Just Shipped A Dazzling Upgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) Estimates
Arcus Biosciences, Inc. (NYSE:RCUS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts greatly increased t
Despite Lacking Profits Arcus Biosciences (NYSE:RCUS) Seems To Be On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Arcus Biosciences(RCUS.US) Q1 2024 Earnings Conference
The following is a summary of the Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript:Financial Performance:Arcus Biosciences reported that they have over $1 billion of cash on hand, which
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target
Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.
Arcus Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 87.5% Wedbush → $30 Reiterates Outperform → Outperform 03/25/2024 212.5% Truist Securities → $5
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)
Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Arcus Biosciences: Holding Steady Amidst Progress and Uncertainties
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences Q1 2024 GAAP EPS $(0.05) Beats $(0.98) Estimate, Sales $145.000M Beat $33.862M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.98) by 94.9 percent. This is a 95.41 percent increase over losses of $(1.0
Express News | Arcus Biosciences Inc -Well-Positioned to Advance Full Pipeline With $1.1 Bln in Cash, Cash Equivalents and Marketable Securities and Runway Into 2027